GlassScriptPhysician profile
Karim Sayad
NPI 1447207428
$1,520.67
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $650 · 2021: $396 · 2022: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $281.64 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $198.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.11 | 2021-2022 | |
| Qol Medical, LLC | $174.99 | 2021 | |
| Allergan, INC. | $172.47 | 2019-2020 | |
| Gilead Sciences, INC. | $125.00 | 2020 | |
| Redhill Biopharma INC. | $121.03 | 2020-2021 | |
| Concordia Pharmaceuticals INC. | $64.80 | 2019 | |
| Ironwood Pharmaceuticals, INC | $54.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.89 | 2019-2020 | |
| Chiesi USA, INC. | $49.28 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.57 | 2021 | |
| Braintree Laboratories, INC. | $14.41 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Sayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.